Type 2 Diabetes Mellitus Clinical Trial
Official title:
A Multicenter, Randomized, Double-Blind, Placebo Controlled, Parallel Group, Phase III Trial to Evaluate the Safety and Efficacy of Dapagliflozin as Monotherapy in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control With Diet and Exercise
Verified date | April 2017 |
Source | AstraZeneca |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this clinical research study is to learn if BMS-512148 (Dapagliflozin) can help reduce the blood sugar levels in subjects with Type 2 Diabetes who are not well controlled on diet and exercise alone. The safety of this treatment will also be studied
Status | Completed |
Enrollment | 497 |
Est. completion date | December 29, 2009 |
Est. primary completion date | December 29, 2009 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 77 Years |
Eligibility |
Inclusion Criteria: - Male and females, =18 to =77 years old, with type 2 diabetes mellitus - Subjects must have central laboratory pre-randomization A1C =7.0 and = 10.0% - C-peptide = 1.0 ng/mL (0.34 nmol/L) - Body Mass Index = 45 kg/m² - Must be able to perform self monitoring of blood glucose Exclusion Criteria: - aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) >3* upper limit of normal (ULN) - Serum Total bilirubin >2 mg/dL (34.2 µmol/L) - Creatinine kinase >3* ULN - Serum creatinine =1.50 mg/dL (133 µmol/L) for male subjects, =1.40 mg/dL (124 µmol/L) for female subjects - Currently unstable or serious cardiovascular, renal, hepatic, hematological, oncological, endocrine, psychiatric, or rheumatic diseases |
Country | Name | City | State |
---|---|---|---|
Canada | Local Institution | Ajax | Ontario |
Canada | Local Institution | Bathurst | New Brunswick |
Canada | Local Institution | Calgary | Alberta |
Canada | Local Institution | Coquitlam | British Columbia |
Canada | Local Institution | Drummondville | Quebec |
Canada | Local Institution | L'Ancienne Lorette | Quebec |
Canada | Local Institution | St-Leonard | Quebec |
Canada | Local Institution | Toronto | Ontario |
Canada | Local Institution | Waterloo | Ontario |
Canada | Local Institution | Winnipeg | Manitoba |
India | Local Institution | Ahmedabad | |
India | Local Institution | Bangalore | |
India | Local Institution | Bangalore | |
India | Local Institution | Jaipur | |
India | Local Institution | Jaipur | |
Mexico | Local Institution | Df | Distrito Federal |
Mexico | Local Institution | Durango | |
Mexico | Local Institution | Guadalajara | Jalisco |
Mexico | Local Institution | Merida | Yucatan |
Mexico | Local Institution | Mexico City | |
Mexico | Local Institution | Monterrey | Nuevo Leon |
Mexico | Local Institution | Veracruz | |
Puerto Rico | Local Institution | Ponce | |
Puerto Rico | Local Institution | Ponce | |
Russian Federation | Local Institution | Kursk | |
Russian Federation | Local Institution | Saint-Petersburg | |
Russian Federation | Local Institution | Saratov | |
Russian Federation | Local Institution | Smolensk | |
Russian Federation | Local Institution | St. Petersburg | |
Russian Federation | Local Institution | St. Petersburg | |
Russian Federation | Local Institution | St. Petersburg | |
Russian Federation | Local Institution | St.Petersburg | |
South Africa | Local Institution | Benoni | Gauteng |
South Africa | Local Institution | Paarl | Western Cape |
South Africa | Local Institution | Soweto | Gauteng |
South Africa | Local Institution | Tygerberg | Western Cape |
United States | James J. Brown, Md | Akron | Ohio |
United States | Central Florida Clinical Trials, Inc. | Altamonte Springs | Florida |
United States | Belzoni Clinical Research | Belzoni | Mississippi |
United States | Valley Research | Fresno | California |
United States | Family Physicians Of Greeley | Greeley | Colorado |
United States | R-Research | Hamilton | New Jersey |
United States | Westside Center For Clinical Research | Jacksonville | Florida |
United States | Dedicated Clinical Research | Litchfield Park | Arizona |
United States | Marina Raikhel, Md, Faafp | Lomita | California |
United States | Richard S. Cherlin, Md | Los Gatos | California |
United States | Panhandle Family Care Associates | Marianna | Florida |
United States | Avastra Clinical Trials | Midvale | Utah |
United States | Down East Medical Associates, Pa | Morehead City | North Carolina |
United States | Coastal Connecticut Research, Llc | New London | Connecticut |
United States | Integris Family Care South | Oklahoma | Oklahoma |
United States | Capital Clinical Research Center | Olympia | Washington |
United States | 43rd Medical Associates, P.C. | Phoenix | Arizona |
United States | Endocrine Research Solutions, Inc. | Roswell | Georgia |
United States | Optimum Clinical Research, Inc. | Salt Lake City | Utah |
United States | Abbott Clinical Research Group, Inc | San Antonio | Texas |
United States | Stephen G. Danley, Do | Spokane | Washington |
United States | Internist Associates Of Central New York | Syracuse | New York |
United States | Southeastern Research Associates, Inc. | Taylors | South Carolina |
United States | Clinical Research Advantage, Inc. | Tempe | Arizona |
United States | Orange County Research Center | Tustin | California |
United States | Southgate Medical Group | West Seneca | New York |
Lead Sponsor | Collaborator |
---|---|
AstraZeneca | Bristol-Myers Squibb |
United States, Canada, India, Mexico, Puerto Rico, Russian Federation, South Africa,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Adjusted Mean Change From Baseline in Hemoglobin A1c (HbA1c) at Week 24 Last Observation Carried Forward (LOCF) - All Randomized Participants | Adjusted mean change in HbA1c from baseline at Week 24, or the last post-baseline measurement prior to Week 24 if no Week 24 assessment was available was determined(LOCF). HbA1c was measured as percent of hemoglobin by a central laboratory. Data after rescue medication (metformin) was excluded from this analysis. Baseline was defined as the last assessment prior to the start date and time of the first dose of the double-blind study medication. In cases where time of the first dose or time of the assessment was not available, baseline was defined as the last assessment on or prior to the date of the first dose of the double-blind study medication. HbA1c values were obtained at enrollment, lead-in, and at Day 1, Weeks 4, 8, 12, 16, 20, and 24 in the double-blind period. | Baseline (Day 1), Week 24 | |
Secondary | Adjusted Mean Change From Baseline in Total Body Weight at Week 24 (LOCF) - Randomized Participants | Adjusted mean change in total body weight from baseline at Week 24, or the last post-baseline measurement prior to Week 24 if no Week 24 assessment was available LOCF was determined. Data after rescue medication (metformin) was excluded from this analysis. Baseline was defined as the last assessment prior to the start date and time of the first dose of the double-blind study medication. In cases where time of the first dose or time of the assessment was not available, baseline was defined as the last assessment on or prior to the date of the first dose of the double-blind study medication. Body weight was measured in kilograms (kg) at qualification, lead-in, Day 1, Weeks 1, 2, 4, 8, 12, 16, 20, and 24 during double-blind period. | Baseline (Day 1), Week 24 | |
Secondary | Adjusted Mean Change From Baseline in Fasting Plasma Glucose at Week 24 (LOCF) - Randomized Participants | Adjusted mean change in fasting plasma glucose (FPG) from baseline at Week 24 (LOCF) was determined. Data after rescue medication (metformin) was excluded from this analysis. FPG was measured as milligrams per deciliter (mg/dL) by a central laboratory at qualification, lead-in, Day 1, Weeks 1, 2, 4, 8, 12, 16, 20, and 24 during double-blind period. Baseline was defined as the last assessment prior to the start date and time of the first dose of the double-blind study medication. In cases where time of the first dose or time of the assessment was not available, baseline was defined as the last assessment on or prior to the date of the first dose of the double-blind study medication. | Baseline (Day 1), Week 24 | |
Secondary | Adjusted Mean Change From Baseline in Effect on 2-hour Post Liquid Meal Glucose at Week 24 (LOCF) - Randomized Participants | Liquid meal tolerance tests (MTTs) were scheduled to occur at Day 1 visit (MTT was to be completed 2 hours prior to first dose of treatment) and at Week 24 / End of treatment visit, or Rescue visit for participants meeting criteria for rescue due to lack of glycemic control. At Week 24, study treatment was given 1 hour before MTT was administered. Participant fasted for at least 10 hours (h) prior to both visits and abstained from tobacco, alcohol, and caffeine for 24 h prior to the MTT. The liquid meal supplement was administered over 10 minutes, starting immediately after Time 0 blood sample was drawn. Blood samples for post-liquid meal Glucose were obtained at 30, 60, 120, and 180 minutes after ingesting the liquid supplement. Glucose was measured in milligrams per deciliter (mg/dL) by a central laboratory. Baseline was defined as the last assessment prior to the start date and time of the first dose of double-blind study medication. | Baseline (Day 1), Week 24 | |
Secondary | Adjusted Percentage of Participants Achieving a Therapeutic Glycemic Response at Week 24 (LOCF) - Randomized Participants | Therapeutic glycemic response was defined as HbA1c less than 7.0%. n=Number of participants with HBA1c less than (<) 7 % at Week 24, last observation carried forward (LOCF) while N=number of randomized participants with non-missing baseline and Week 24 (LOCF) values. Percent=n/N and was adjusted for Baseline HbA1c. Data after rescue medication (metformin) was excluded from this analysis. HbA1c was measured as a percent of hemoglobin. | Baseline (Day 1), Week 24 | |
Secondary | Adjusted Mean Change From Baseline in Waist Circumference at Week 24 (LOCF) - Randomization Participants | Adjusted mean waist circumference values from baseline to Week 24 (or the last post-baseline measurement prior to Week 24 if no Week 24 assessment was available, last observation carried forward, (LOCF) was determined. Data after rescue medication (metformin) was excluded from this analysis. Waist circumference was measured centimeters (cm) and obtained at lead-in, Day 1, and Week 24 of the double-blind period. Baseline was defined as the last assessment prior to the start date and time of the first dose of the double-blind study medication. In cases where time of the first dose or time of the assessment was not available, baseline was defined as the last assessment on or prior to the date of the first dose of the double-blind study medication. | Baseline (Day 1), Week 24 | |
Secondary | Number of Participants With Deaths, Serious AEs (SAEs), Adverse Events (AEs), Discontinuation Due to AEs, During the 12 Week Double Blind Period, Including Data After Rescue - All Treated Participants | Medical Dictionary for Regulatory Activities (MedDRA), version 12.1 AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Treatment-related=having certain, probable, possible, or missing relationship to study drug as per the investigator. Baseline to last dose plus 4 days for AEs, plus 30 days for SAEs. Data after rescue included. | Day 1 of Double Blind Period to end of Week 24 Plus 30 days | |
Secondary | Number of Participants With Adverse Events of Special Interest During the 12 Week Double Blind Period - All Treated Participants | Participants with AEs of hypoglycemia, cardiac/vascular disorders, renal impairment or failure, volume depletion (hypotension/dehydration/hypovolemia), fractures, urinary stones, and other reports suggestive of genital infection or urinary tract infection (UTI) were summarized using MedDRA version 12.1. Data after rescue included for all AEs of special interest except hypoglycemia; hypoglycemia AEs were prior to rescue. Major hypoglycemic episode: symptomatic requiring 3rd party assistance due to severe impairment in consciousness or behavior with a glucose value < 54 mg/dL and prompt recovery after glucose/glucagon; Minor: either symptomatic with glucose measurement < 63 mg/dL, regardless of need for 3rd party assistance, or asymptomatic with glucose < 63 mg/dL that does not qualify as major; Other: suggestive but not meeting criteria for major or minor. | Baseline to last dose plus 4 days in 12 Week Double Blind Period | |
Secondary | Mean Change From Baseline in Seated Systolic and Diastolic Blood Pressure at Week 24, Including Data After Rescue - Treated Participants | Blood pressure values were obtained on Day 1, Weeks 1, 2, 4, 8, 12, 16, 20, and 24 in the double blind period, after the participant was seated for quietly for 5 minutes; the same arm (right or left) was used consistently through out the study. Measurements were taken at least 10 hours after the last ingestion of caffeine, alcohol, or nicotine. Blood pressure was measured in millimeters of mercury (mmHg). Data after rescue were also included. Baseline was defined as the last assessment prior to the start date and time of the first dose of the double-blind study medication. In cases where time of the first dose or time of the assessment was not available, baseline was defined as the last assessment on or prior to the date of the first dose of the double-blind study medication. | Baseline (Day 1), Week 24 | |
Secondary | Mean Change From Baseline in Seated Heart Rate at Week 24 - Treated Participants | Heart rate values were obtained after the participant was seated for quietly for 5 minutes; the same arm (right or left) was used consistently through out the study. Measurements were taken at least 10 hours after the last ingestion of caffeine, alcohol, or nicotine. Heart rate was measured in beats per minute (bpm). Data after rescue were also included. Baseline was defined as the last assessment prior to the start date and time of the first dose of the double-blind study medication. In cases where time of the first dose or time of the assessment was not available, baseline was defined as the last assessment on or prior to the date of the first dose of the double-blind study medication. | Baseline (Day 1), Week 24 | |
Secondary | Number of Participants With Normal or Abnormal Electrocardiogram Summary Tracing at Week 24 (LOCF) - Treated Participants | 12-Lead electrocardiograms (ECGs) were performed at Day -14 and Week 24/End of treatment visit (last observation carried forward) on participants who were supine. ECGs were assessed by the investigator. Baseline (BL) was Day -14 for this parameter. | Week 24 | |
Secondary | Number of Participants With Marked Laboratory Abnormalities in 24 Week Double Blind Treatment Period - Treated Participants | Safety laboratory measurements were obtained at Day 1, Weeks 1, 2, 4, 8, 12, 20, and 24 in the double blind Period. Baseline was defined as the last assessment prior to the start of the first dose of the double-blind study medication. Data included from baseline up to and including the last day of treatment plus 4 days. Data after rescue was also included. Abbreviations; Pretreatment (PreRX); grams per deciliter (g/dL); upper limit of normal (ULN); milliequivalent per liter (mEq/L); greater than (>) less than (<); Units per liter (U/L), alanine aminotransferase (ALT); aspartate aminotransferase (AST); alkaline phosphatase (ALP); blood urea nitrogen (BUN). Marked abnormality Low (High) defined: hemoglobin <6 (>18 females or >20 males) g/dL; hematocrit <20% ( >55% females or >60% males); BUN (>60 mg/dL) or Urea >21.4 mmol/L; creatinine (>=1.5*preRX, >=2.5 mg/dL); AST and ALT >3*ULN; bilirubin >1.5*ULN; ALP >1.5*ULN. | Baseline to Week 24/end of treatment plus 4 days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02771093 -
An Exploratory Study of the Effects of Trelagliptin and Alogliptin on Glucose Variability in Patients With Type 2 Diabetes Mellitus
|
Phase 4 | |
Completed |
NCT02545842 -
Assessment Study of Three Different Fasting Plasma Glucose Targets in Chinese Patients With Type 2 Diabetes Mellitus (BEYOND III/FPG GOAL)
|
Phase 4 | |
Recruiting |
NCT03436212 -
Real-Life Home Glucose Monitoring Over 14 Days in T2D Patients With Intensified Therapy Using Insulin Pump.
|
N/A | |
Completed |
NCT03244800 -
A Study to Investigate Different Doses of 0382 in Overweight and Obese Subjects With Type 2 Diabetes Mellitus.
|
Phase 2 | |
Completed |
NCT03960424 -
Diabetes Management Program for Hispanic/Latino
|
N/A | |
Withdrawn |
NCT02769091 -
A Study in Adult Patients With Nonalcoholic Steatohepatitis Who Also Have Type 2 Diabetes
|
Phase 2 | |
Recruiting |
NCT06065540 -
A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor
|
Phase 3 | |
Recruiting |
NCT05008276 -
Puberty, Diabetes, and the Kidneys, When Eustress Becomes Distress (PANTHER Study)
|
||
Completed |
NCT04091373 -
A Study Investigating the Pharmacokinetics of a Single Dose Administration of Cotadutide
|
Phase 1 | |
Completed |
NCT03296800 -
Study to Evaluate Effects of Probenecid, Rifampin and Verapamil on Bexagliflozin in Healthy Subjects
|
Phase 1 | |
Recruiting |
NCT05979519 -
Fresh Carts for Mom's to Improve Food Security and Glucose Management
|
N/A | |
Recruiting |
NCT06212778 -
Relationship Between Nutritional Status, Hand Grip Strength, and Fatigue in Hospitalized Older Adults With Type 2 Diabetes Mellitus.
|
||
Recruiting |
NCT05579314 -
XW014 in Healthy Subjects and Patients With Type 2 Diabetes Mellitus (T2DM)
|
Phase 1 | |
Completed |
NCT03859934 -
Metabolic Effects of Melatonin Treatment
|
Phase 1 | |
Terminated |
NCT03684642 -
Efficacy and Safety of Efpeglenatide Versus Dulaglutide in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin
|
Phase 3 | |
Completed |
NCT03248401 -
Effect of Cilostazol on Carotid Atherosclerosis Estimated by 3D Ultrasound in Patients With Type 2 Diabetes
|
Phase 4 | |
Completed |
NCT03644134 -
A Personalized Intervention to Manage Physiological Stress and Improve Sleep Patterns
|
N/A | |
Completed |
NCT05295160 -
Fasting-Associated Immune-metabolic Remission of Diabetes
|
N/A | |
Completed |
NCT02836873 -
Safety and Efficacy of Bexagliflozin in Type 2 Diabetes Mellitus Patients With Moderate Renal Impairment
|
Phase 3 | |
Completed |
NCT02252224 -
Forxiga (Dapagliflozin) Regulatory Postmarketing Surveillance
|